Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22382881)

  • 1. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
    Liu Q; Sun JD; Wang J; Ahluwalia D; Baker AF; Cranmer LD; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1487-98. PubMed ID: 22382881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
    Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
    Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
    Heinemann V
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
    Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
    Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 12. A landmark point analysis with cytotoxic agents for advanced NSCLC.
    Yamamoto N; Nambu Y; Fujimoto T; Koshiji M
    J Thorac Oncol; 2009 Jun; 4(6):697-701. PubMed ID: 19318995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The present and future of combination chemotherapy in bladder cancer.
    Culine S
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Kotsakis A; Hatzidaki D; Vamvakas L; Vardakis N; Kalykaki A; Bozionelou V; Androulakis N; Kalbakis K; Saridaki Z; Georgoulias V; Agelaki S
    Anticancer Res; 2010 Oct; 30(10):4335-42. PubMed ID: 21036760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
    Misset JL
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):36-9. PubMed ID: 11894006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY; Eckardt J; Scagliotti GV
    Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
    Standfield L; Weston AR; Barraclough H; Van Kooten M; Pavlakis N
    Respirology; 2011 Nov; 16(8):1210-20. PubMed ID: 21801275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based combination treatment of pancreatic cancer.
    Heinemann V
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):25-35. PubMed ID: 11894005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
    Monnerat C; Le Chevalier T
    Ann Oncol; 2006 May; 17 Suppl 5():v86-90. PubMed ID: 16807472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.